Adverum Biotechnologies, Inc.
ADVM
$2.91
-$0.06-2.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 59.70% | -1.45% | -17.00% | -26.82% | -26.44% |
| Gross Profit | -59.70% | 6.27% | 17.00% | 11.74% | 26.44% |
| SG&A Expenses | 137.95% | -29.06% | -69.64% | -10.57% | 85.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.00% | -12.48% | -36.85% | -20.69% | 6.80% |
| Operating Income | -100.00% | 15.37% | 36.85% | 11.24% | -6.80% |
| Income Before Tax | -103.13% | 17.45% | 41.33% | 14.64% | 8.92% |
| Income Tax Expenses | -- | -- | -- | -- | -6,063.16% |
| Earnings from Continuing Operations | -111.16% | 17.49% | 41.36% | 14.69% | 12.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.16% | 17.49% | 41.36% | 14.69% | 12.44% |
| EBIT | -100.00% | 15.37% | 36.85% | 11.24% | -6.80% |
| EBITDA | -104.01% | 14.20% | 36.81% | 9.79% | -9.79% |
| EPS Basic | -2.27% | 60.08% | 71.66% | 48.08% | 13.55% |
| Normalized Basic EPS | 1.62% | 60.06% | 71.64% | 48.05% | -5.43% |
| EPS Diluted | -2.27% | 60.08% | 71.66% | 48.08% | 13.55% |
| Normalized Diluted EPS | 1.62% | 60.06% | 71.64% | 48.05% | -5.43% |
| Average Basic Shares Outstanding | 106.48% | 106.69% | 106.93% | 64.30% | 1.29% |
| Average Diluted Shares Outstanding | 106.48% | 106.69% | 106.93% | 64.30% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |